Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

被引：0
|
作者：
Keystone, Edward [1 ]
van Vollenhoven, Ronald F. [2 ]
Wilkinson, Bethanie [3 ]
Fallon, Lara [4 ]
Hwang, Lie-Ju [5 ]
Chapman, Douglass [5 ]
DeMasi, Ryan [5 ]
Lee, Eun Bong [6 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON, Canada
[2] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Canada, Montreal, PQ, Canada
[5] Pfizer Inc, New York, NY USA
[6] Seoul Natl Univ, Seoul, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1608
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Lack of early change in DAS28-4(ESR) predicts the likelihood of achieving LDA at month 6: tofacitinib monotherapy vs. MTX in MTX-naive patients with RA
    DeMasi, R.
    Keystone, E.
    van Vollenhoven, R.
    Wilkinson, B.
    Fallon, L.
    Hwang, L-J
    Chapman, D.
    Lee, E. B.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 19 - 20
  • [22] The relation of disease activity and methotrexate with the risk of cardiovascular disease in patients with rheumatoid arthritis
    Welsing, PMJ
    Kievit, W
    Fransen, J
    Van Riel, PLCM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 90 - 90
  • [23] Disease activity score predicts costs in patients with rheumatoid arthritis
    Hernández-Cruz, B
    Ariza-Ariza, R
    Ruiz-Montesinos, D
    Carmona, L
    Ballina, J
    Navarro-Sarabia, F
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S506 - S507
  • [24] Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate
    Lee, Yvonne C.
    Cui, Jing
    Costenbader, Karen H.
    Shadick, Nancy A.
    Weinblatt, Michael E.
    Karlson, Elizabeth W.
    RHEUMATOLOGY, 2009, 48 (06) : 613 - 617
  • [25] Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
    Kaine, Jeffrey
    Kivitz, Alan J.
    Mysler, Eduardo
    Iikuni, Noriko
    Fan, Haiyun
    Diehl, Annette
    Paulissen, Jerome
    Murray, Christopher W.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [26] Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naive Patients with Early Rheumatoid Arthritis
    Movahedi, Mohammad
    Weber, Deborah
    Akhavan, Pooneh
    Keystone, Edward
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [27] PROGNOSTIC NUTRITIONAL INDEX CORRELATES WITH DISEASE ACTIVITY SCORE AFTER METHOTREXATE INITIATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Yoshii, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [28] Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
    Keystone, Edward C.
    Breedveld, Ferdinand C.
    van der Heijde, Desiree
    van Vollenhoven, Ronald F.
    Florentinus, Stefan
    Faccin, Freddy
    Liu, Shufang
    Kupper, Hartmut
    Kavanaugh, Arthur
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S559 - S559
  • [29] Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate versus Methotrexate Alone
    Keystone, Edward
    Breedveld, Ferdinand
    Van der Heijde, Desiree
    Van Vollenhoven, Ronald
    Florentinus, Stefan
    Faccin, Freddy
    Liu, Shufang
    Kupper, Hartmut
    Kavanaugh, Arthur
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 996 - 996
  • [30] ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE
    Keystone, E. C.
    Breedveld, F. C.
    van der Heijde, D.
    van Vollenhoven, R. F.
    Florentinus, S.
    Faccin, F.
    Liu, S.
    Kupper, H.
    Kavanaugh, A. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 228 - 228
12345